# Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026

- Link: https://www.thailand-business-news.com/pr-news/lundbeck-presents-new-vyepti-eptinezumab-and-bocunebart-migraine-portfolio-data-at-ean-2026
- Published: 2026-06-24T15:08:00+07:00
- Author: PR Newswire

◦ Five migraine presentations will showcase Lundbeck’s current and future approaches
   to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED
   primary data for the investigational treatment, bocunebart
 ◦ Eptinezumab data explore patient-centered outcomes in chronic migraine beyond
   traditional endpoints, including acute medication use, psychological well-being,
   and workplace productivity           
 ◦ Late breaker bocunebart presentation will provide further insight into pituitary
   adenylate cyclase-activating polypeptide (PACAP) pathway inhibition as a potential
   novel approach to migraine prevention in patients with prior preventive treatment
   failures           
 ◦ Lundbeck’s EAN 2026 program underscores the company’s commitment to addressing
   the broader burden of the disease and continued scientific innovation around 
   existing unmet needs

VALBY, Denmark, June 24, 2026 /PRNewswire/ — H. Lundbeck A/S (Lundbeck) today announced
that new migraine clinical data will be presented at the European Academy of Neurology(
EAN) Congress 2026, taking place 27–30 June in Geneva, Switzerland. The presentations
will include new analyses of eptinezumab data, exploring outcomes that reflect the
wider burden of chronic migraine beyond migraine frequency alone. Lundbeck will 
also present Phase IIb PROCEED primary data for bocunebart, an investigational treatment
targeting pituitary adenylate cyclase-activating polypeptide (PACAP) in development
for migraine prevention.

Together, these EAN presentations highlight Lundbeck’s dual focus in migraine: optimizing
the use of current preventive treatment options while advancing future therapeutic
approaches for people who continue to experience substantial disease burden.

**Bocunebart data provide insight into PACAP pathway inhibition in migraine prevention**

Among the highlights at EAN 2026 are data for bocunebart, a monoclonal antibody (
mAb) designed to inhibit PACAP, a neuropeptide implicated in migraine pathophysiology
distinct from anti-calcitonin gene-related peptide (aCGRP). PROCEED evaluated the
efficacy, safety, dosing and route of administration of bocunebart in adults with
migraine for whom one to four prior preventive treatments had failed.

"The presentation advances the evolving scientific understanding of PACAP pathway
inhibition as a potential novel approach to migraine prevention for patients that
continue to experience suboptimal disease control despite current preventive treatment
options," said Andrew Blumenfeld MD, Cedars Sinai Los Angeles and presenter of the
PROCEED findings at EAN 2026.

**Eptinezumab data highlight patient-centered measures of migraine prevention**

Lundbeck will also present new analyses from the Phase III SUNRISE and Phase IV 
RESOLUTION trials on eptinezumab, exploring treatment outcomes that reflect the 
wider clinical, functional and psychological burden of migraine.

Three presentations from the RESOLUTION trial will focus on adults living with chronic
migraine and medication-overuse headache (MOH), a patient population in which migraine
prevention is complicated by frequent headache, high acute medication use and substantial
disease burden.

The analyses will examine treatment outcomes with eptinezumab across different European
countries, patterns of acute medication use over time, and changes in symptoms of
anxiety and depression that commonly accompany chronic migraine. In addition, the
SUNRISE analysis will explore the impact of eptinezumab on workplace productivity
and activity impairment in chronic migraine across regions in Asia and Europe.

"The burden of migraine extends well beyond the number of headache days. For many
people living with migraine, the disease can affect multiple aspects of daily life,
yet these impacts are not always fully captured in traditional measures of treatment
benefit," said Johan Luthman, Executive Vice President and Head of Research & Development
at Lundbeck. "At EAN 2026, we are presenting data that reflect a broader view of
migraine prevention, while also advancing scientific understanding of PACAP pathway
inhibition through our investigational molecule bocunebart. Together, these presentations
reflect Lundbeck’s commitment to advancing brain health in areas of unmet need."

Details of Lundbeck presentations at EAN 2026

  |

**Data presentations**

  |  
 |

Therapeutic  area

  |

Presentation content

  |

Presentation Type

  |

Reference

  |  
 |

Migraine preventionBocunebart

  |

Efficacy and safety of bocunebart, an anti-PACAP monoclonal antibody, in adults with migraine for whom prior preventive treatments have failed

  |

Late breaking session: Poster presentation

  |

Mon, 29 June  14:15-15:15 CEST (EPO-071) Booth A1

  |  
 |

Migraine preventionEptinezumab

  |

Impact of eptinezumab on acute medication use in participants with chronic migraine and medication-overuse headache: 24-week data from the RESOLUTION trial

  |

ePoster 
Presentation

  |

Sat, 27 June 14:40-14:45 CEST (EPO-0249)

  |  
 |

Migraine preventionEptinezumab

  |

Efficacy of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: country-level results from the RESOLUTION trial

  |

ePoster 
Presentation

  |

Sun, 28 June 15:05-15:10 CEST  EPO-0583

  |  
 |

Migraine preventionEptinezumab

  |

Changes in anxiety and depression symptoms in patients with chronic migraine and medication-overuse headache in the RESOLUTION trial

  |

ePoster 
Presentation

  |

Sat, 27 June 12:45-12:50 CEST  EPO-0083 

  |  
 |

Migraine prevention  Eptinezumab

  |

Impact on workplace productivity following preventive treatment with eptinezumab: region-based analyses from the Phase III SUNRISE trial

  |

ePoster 
Presentation

  |

Sun, 28 June 13:25-13:30 CEST  EPO-0416

  |

  |

**Sponsored scientific symposium and forum presentation**

  |  
 |

Therapeutic area

  |

Title

  |

Speakers

  |

Reference

  |  
 |

Migraine

  |

Optimizing the treatment trajectory: Raising the bar for migraine prevention

  |

Piero Barbanti, Andreas 
Gantenbein, Francesca Puledda

  |

Sun, 28 June 14:15-15:15 CEST 
Room: Vienna

  |  
 |

Multiple system 
atrophy (MSA)

  |

Recognizing multiple system atrophy: From early symptoms to timely referral and diagnosis

  |

Günter Höglinger

  |

Sun, 28 June 10:15-10:30 CEST
Venue: Scientific Theatre 

  |

About migraine 
Migraine is a complex and incapacitating neurological disease characterized
by recurrent episodes of severe headaches typically accompanied by an array of symptoms,
including nausea, vomiting, and sensitivity to light or sound.^([1]) Not only is
migraine painful but also imposes both a social and financial burden. Migraine has
a profound impact on patient functioning including relationships with family/friends,
leisure activities, household production and work productivity.

Migraine is one of the most prevalent neurological diseases for which medical treatment
is sought and is considered the leading cause of disability for people under the
age of 50 and the 2nd leading cause of disability worldwide.^([2])^(,[3]) Repeated
migraine attacks, and often the constant fear of the next one, damage family life,
social life and work life. As migraine frequency and severity increase, attacks 
become harder to control, requiring patients to take more headache medication while
experiencing less relief. This cycle contributes to a greater disease burden and,
without appropriate preventive management, can lead to further worsening and chronification
of migraine.^([4])

About Vyepti® (eptinezumab)
Eptinezumab is a humanized mAb that binds to CGRP which
was developed for intravenous (IV) administration. The efficacy and safety of eptinezumab
100 mg and 300 mg was investigated in two Phase III clinical trials (_PROMISE-1_
in episodic migraine^([5]) and _PROMISE-2_ in chronic migraine).^([6]) In both trials,
eptinezumab met its primary endpoint of reducing mean monthly migraine days (MMD)
over weeks 1-12 in both episodic and chronic migraine. The safety of eptinezumab
was evaluated in more than 2,000 adult patients with migraine who received at least
one dose of eptinezumab. The most common adverse reactions (≥2% and at least 2% 
or greater than placebo) in the clinical trials for the preventive treatment of 
migraine were nasopharyngitis and hypersensitivity. Approximately 8% of patients
on 300 mg, 6% of patients on 100 mg and 6% of patients on placebo in _PROMISE-1_
and _PROMISE-2_ experienced nasopharyngitis. In _PROMISE-1_ and _PROMISE-2_, 1.9%
of patients treated with eptinezumab discontinued treatment due to adverse reactions.

VYEPTI (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (
FDA) for the preventive treatment of migraine in adults in February 2020, and in
January 2022, eptinezumab was granted marketing authorization by the European Commission(
EC) for the prophylaxis of migraine in adults who have at least four migraine days
per month. Today, eptinezumab is launched in more than 30 markets worldwide.

About the SUNRISE trial 
SUNRISE (NCT04921384) was an interventional, multi-regional,
multi-site, randomized, double-blind, placebo-controlled Phase III trial, to confirm
the efficacy and safety of eptinezumab in participants with chronic migraine who
are eligible for preventive treatment.^(2) The trial enrolled 983 adult participants
who were randomly allocated to one of three treatment groups: eptinezumab 300 mg,
eptinezumab 100 mg, or placebo.

The primary endpoint was the change from baseline in monthly migraine days (MMDs)
during Weeks 1–12. Key secondary endpoints included the achievement of a ≥ 50% reduction
in MMDs over Weeks 1–12, achievement of a ≥ 75% reduction in MMDs over Weeks 1–4
and Weeks 1–12, and the percentage of participants experiencing a migraine on Day
1. Other secondary and exploratory endpoints assessed overall migraine responder
rates, long-term maintenance of effect, and the safety and tolerability of eptinezumab
in this patient population. The trial was conducted to support marketing authorization
across Asia.

About the RESOLUTION trial
The RESOLUTION trial (NCT05452239) was a Phase IV, multi-
national, randomized, double-blind, placebo-controlled trial. The trial enrolled
608 participants with dual diagnoses of chronic migraine and MOH, and participants
were randomly allocated to one of two treatment groups, brief educational intervention(
BEI) and eptinezumab (100 mg; n = 305) or BEI and placebo (n = 303), in a 1:1 ratio.

RESOLUTION is the first randomized controlled trial to assess the efficacy of an
anti-CGRP treatment in combination with structured patient education in chronic 
migraine and MOH. The primary endpoint was the change from baseline in monthly migraine
days over weeks 1-4. Key secondary endpoints included change from baseline in average
daily pain assessment score (as accessed by 3-point pain intensity scale, mild, 
medium, severe) and change from baseline in acute medication use over 1-12 weeks.
Other secondary and exploratory endpoints assessed monthly migraine days over weeks
1-12, MOH remission, transition from chronic to episodic migraine, reductions in
headache-related burden, migraine-related disability, work productivity loss, activity
impairment, and the safety and tolerability of eptinezumab in this patient population.
The participants in the RESOLUTION trial were mainly from European countries.

About bocunebart
Bocunebart is an investigational mAb with a novel mechanism of 
action. It was engineered to bind to and inhibit the signaling of PACAP, a neuropeptide
implicated in migraine pathophysiology. This mechanism operates through a pathway
distinct from that targeted by anti-CGRP therapies.^([7]) Bocunebart met its primary
endpoint in the Phase IIb PROCEED and is being investigated for the preventive treatment
of migraine as a potential alternative approach to existing treatment classes.

Bocunebart is not approved by the US Food and Drug Administration (FDA) or any other
regulatory agency, and the efficacy and safety of bocunebart have not been established.

About the PROCEED migraine trial
The PROCEED (NCT06323928) trial assessed the efficacy,
safety, and tolerability of bocunebart versus placebo when administered once monthly
for three months. The Phase IIb trial was designed to inform dose selection and 
route of administration for future development. In the IV part of PROCEED, a total
of 429 patients from 14 countries were treated. The primary efficacy endpoint was
defined as the difference between bocunebart and placebo in mean change from baseline
in MMDs over Weeks 1 to 12.

The target population for this trial included adults with migraine according to 
the International Classification of Headache Disorders, Third Edition (ICHD-3) who
had experienced treatment failure with one to four different preventive migraine
medications within the past 10 years.

**Contacts**

Anders Crillesen                                Jens Høyer    
Senior Director, 
Vice President,   Internal & External Relations             Head of Investor Relations
[AECE@lundbeck.com](https://www.thailand-business-news.com/pr-news/AECE@lundbeck.com)
[JSHR@lundbeck.com](https://www.thailand-business-news.com/pr-news/JSHR@lundbeck.com)
+45 27 79 12 86                                +45 30 83 45 01

About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively
on brain health. With more than 70 years of experience in neuroscience, we are committed
to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world’s population, and the effects are
felt throughout society. With the rapidly improving understanding of the biology
of the brain, we hold ourselves accountable for advancing brain health by curiously
exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle
some of the most complex neurological challenges. We develop transformative medicines
targeting people for whom there are few or no treatments available, expanding into
neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive
to create long term value for our shareholders by making a positive contribution
to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products
are available in more than 80 countries. For additional information, we encourage
you to visit our corporate site [www.lundbeck.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4718599-1&h=2679609501&u=https%3A%2F%2Fwww.lundbeck.com%2Fglobal&a=www.lundbeck.com)
and connect with us via [LinkedIn](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4718599-1&h=1500105865&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flundbeck%2F&a=LinkedIn).

**References: **

^([1]) Headache Classification Committee of the International Headache Society (
IHS). The International Classification of Headache Disorders, 3rd Edition. 2018.
38(1): p. 1-211.

^([2]) Steiner TJ, et al. J Headache Pain. 2018;19(1):17. 

^([3]) Leonardi M, et al. J Headache Pain. 2005; 6(6):429– 440. 

^([4]) Lipton RB, et al. J Neurol. 2023;270(12);5692–5710.

^([5]) Ashina M, et al. Cephalalgia. 2020;40(3):241-254. 

^([6]) Lipton RB, et al. Neurology. 2020;94(13):e1365-e1377.

^([7]) Al-Karagholi, M.AM., Zhuang, Z.A., Beich, S. et al. J Headache Pain 26, 79(
2025).

**CONTACT: **

H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark+45 3630 1311[info@lundbeck.com](https://www.thailand-business-news.com/pr-news/info@lundbeck.com)

This information was brought to you by Cision [http://news.cision.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4718599-1&h=742943490&u=http%3A%2F%2Fnews.cision.com%2F&a=http%3A%2F%2Fnews.cision.com)

[https://news.cision.com/h–lundbeck-a-s/r/lundbeck-presents-new-vyepti—eptinezumab–and-bocunebart-migraine-portfolio-data-at-ean-2026,c4366131](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4718599-1&h=4044110307&u=https%3A%2F%2Fnews.cision.com%2Fh--lundbeck-a-s%2Fr%2Flundbeck-presents-new-vyepti---eptinezumab--and-bocunebart-migraine-portfolio-data-at-ean-2026%2Cc4366131&a=https%3A%2F%2Fnews.cision.com%2Fh--lundbeck-a-s%2Fr%2Flundbeck-presents-new-vyepti---eptinezumab--and-bocunebart-migraine-portfolio-data-at-ean-2026%2Cc4366131)

The following files are available for download:

  |

[https://mb.cision.com/Main/18215/4366131/4161834.pdf](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4718599-1&h=1051090202&u=https%3A%2F%2Fmb.cision.com%2FMain%2F18215%2F4366131%2F4161834.pdf&a=https%3A%2F%2Fmb.cision.com%2FMain%2F18215%2F4366131%2F4161834.pdf)

  |

EAN curtain raiser_Final

  |

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026 ](http://www.prnasia.com/story/archive/4991130_AE91130_0?rand=184833)
